Effect of VEGFR, PDGFR and PI3K/mTOR Targeting in Glioblastoma

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Resistance to targeted cancer therapy often arises from redundant signaling pathways mediated by growth factor receptor cross-talk.
• Simultaneous targeting of multiple growth factor receptors is a strategy to overcome this resistance.
• Glioblastoma remains a challenging cancer with significant unmet therapeutic needs.

Purpose of the Study:

• To evaluate the efficacy of single and dual targeting of Platelet-Derived Growth Factor Receptor (PDGFR) and Vascular Endothelial Growth Factor Receptor (VEGFR) in glioblastoma.
• To investigate the effectiveness of inhibiting the Phosphatidylinositol 3-kinase (PI3K)/mammalian Target of Rapamycin (mTOR) pathways in glioblastoma.
• To compare the therapeutic potential of PI3K/mTOR inhibition against PDGFR and VEGFR targeting in glioblastoma.

Main Methods:

• Glioblastoma cells were treated with targeted therapies against PDGFR and VEGFR, individually and in combination.
• The impact of dual PDGFR and VEGFR inactivation on cell death was assessed.
• The efficacy of PI3K/mTOR pathway inhibition was evaluated in glioblastoma cells.

Main Results:

• Single receptor targeting (PDGFR or VEGFR) resulted in moderate glioblastoma cell death.
• Dual PDGFR and VEGFR inactivation showed improved cell death compared to single targeting but lacked synergy.
• Inhibition of PI3K/mTOR pathways demonstrated superior efficacy in inducing glioblastoma cell death compared to PDGFR/VEGFR targeting strategies.

Conclusions:

• Dual targeting of PDGFR and VEGFR is partially effective but not synergistic in glioblastoma.
• PI3K/mTOR pathway inhibition represents a more potent therapeutic strategy for glioblastoma than PDGFR/VEGFR targeting.
• Targeting the PI3K/mTOR pathway holds significant promise for improving glioblastoma treatment outcomes.